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S U M M A R Y
Objectives: The use of cardiac implantable electronic device (CIED; pacemakers, implantable
cardioverter-deﬁbrillators [ICD], cardiac re-synchronized therapy [CRT]) implantation, one essential
treatment for cardiac arrhythmias, is increasing. Infectious complications related to implants are the
main reason for device removal and patient morbidity. We sought to identify the incidence of infectious
complications among patients with cardiac device implantation and analyze the risk factors for
infectious complications.
Methods: A retrospective analysis was conducted of 1307 patients (61.514.2 years-old, 49.6% male) with
cardiac device implantation from January 1990 to April 2013. We analyzed the incidence of infectious
complications during the follow-up period. To investigate risk factors associated with infectious
complications, we conducted a 1:2 matched case-control study of patients with infectious complications
and controls without infectious complications who had the same implantation period and physician.
Results: Among 1307 patients, 12 had a conﬁrmed device-related infection: 7 with a pocket infection and
5 with infective endocarditis. Over a total of 9091.9 device-years, the incidence of infectious
complications was 1.3/1000 device-years, based on the 12 patients with an infection. ICD (5.1/1000
device-year) had a higher incidence of infectious complications than other cardiac devices, and no
infectious complications were observed among patients with CRT implantation. Mean duration from the
time of implantation to infection was 2.021.65 years. In a multivariate analysis, the number of prior
procedures including wound revision or scar revision was an independent risk factor for infectious
complications (OR=10.88, 95% CI 1.11->999, p=0.040).
Conclusions: Infection was a rare complication of cardiac device implantation, but repeated procedures
were associated with infectious complications.
 2015 The Authors. Published by Elsevier Ltd on behalf of International Society for Infectious Diseases.
This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-
nc-nd/4.0/).
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The use of cardiac implantable electronic device (CIED;
pacemakers, implantable cardioverter-deﬁbrillators [ICD], cardiac
re-synchronized therapy [CRT]) implantation, an essential proce-
dure to treat cardiac arrhythmias, is growing. Pacemaker and ICD* Corresponding author. Department of Internal Medicine, Yonsei University
College of Medicine, 50 Yonsei-ro, Seodaemun-gu, Seoul 120-752, Republic of
Korea. Tel.: +82 2 2228 1974; fax: +82 2 393 6884.
E-mail address: seran@yuhs.ac (J.Y. Choi).
http://dx.doi.org/10.1016/j.ijid.2015.05.011
1201-9712/ 2015 The Authors. Published by Elsevier Ltd on behalf of International So
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).implantation has increased by 19% and 60%, respectively, from
1997 to 2004 in the United States.1 A rising trend has been
observed globally, including in Korea.2,3 The reported incidence of
cardiac device-related infections ranges from 0.5%-4.8%.4–7 Al-
though infrequent, infectious complications can cause device
removal and even mortality.8–13 Recent research shows that
diabetes mellitus, underlying heart disease, cardiac resynchro-
nized therapy (CRT)/dual chamber devices and use of >1 lead are
risk factors for cardiac device-related infection.11,14,15 Most
research on cardiac device-related infections has been conducted
in Western countries, and studies in Asian countries are limited.
The current incidence of cardiac device-related infections in Southciety for Infectious Diseases. This is an open access article under the CC BY-NC-ND
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been performed there since 1969.16 There were 5815 cases of
cardiac device implantation in 2006 and 9208 cases in 2013 in
South Korea.17,18 A better understanding of the incidence and risk
factors of infectious complications in the region would help
physicians develop appropriate measures to prevent and treat
cardiac device-related infections.
We conducted this study to investigate the incidence and risk
factors of cardiac device-related infections in South Korea.
2. Methods
2.1. Study population
The study population was composed of patients who under-
went cardiac device (including permanent pacemakers, ICD, CRT)
implantation de novo in a 2000-bed, tertiary teaching hospital
from January 1990 to April 2013 in South Korea. A retrospective
analysis was conducted using the medical records of 1306 patients,
aged 18 years or older, for whom clinical observations and
laboratory ﬁndings were available. We excluded patients who did
not receive regular follow-up or who received an implant in
another hospital but came to our center with an infection.
2.2. Study design and variables
We analyzed the incidence of cardiac device infections among
1307 patients during the follow-up period. Person-years of follow-
up were calculated from the date of cardiac device implantation
until the date of cardiac device infection or the date of last follow-
up visit at the hospital.
Diagnosis of cardiac device infection was made clinically or
microbiologically. We deﬁned clinical evidence of cardiac device
infection as one of the following signs: erythema, tenderness,
ﬂuctuance, warmth, wound dehiscence, skin erosion or discharge
over the generator site.19 Microbiological diagnosis was made
based on positive culture of typical causative agents from the
pocket of the device or its leads.19 We applied modiﬁed Duke
Criteria for the diagnosis of infective endocarditis for the detection
of device-related endocarditis.20
In addition, to identify risk factors for cardiac device infection,
we performed a matched case-control study. Cases included
12 patients with device-related infections during the study period.
The control group consisted of 24 patients who underwent cardiac
device implantation during the same period without infections
during follow-up. Two controls were matched to each case
according to implantation period within a month and the physician
who did the procedure.
The following variables were assessed: (1) demographic and
clinical characteristics (age at cardiac device implantation, gender,
body mass index and Charlson comorbidity index.21 Presence ofTable 1
Incidence of infectious complications of cardiac implantable electronic devices
Device
Total PM 
Number (n,%) 1,307 1,130 
Age (Years) 61.514.2 62.5
Gender (male; n,%) 634 (49.6) 496 
Total FU duration (Device-yr) 9,091.95 8,442.2
No. of infection complications (n,%) 12 (0.9) 9 
Incidence (/1,000Device-yr) 1.3 1.0
Type of infection
Pocket infection (n,%) 7 (0.5) 5 
Endocarditis (n,%) 5 (0.4) 4 
PM: Pacemaker, ICD: implantable cardioverter deﬁbrillator, CRT: cardiac resynchronizearterial hypertension, diabetes, myocardial infarction, heart failure
(ejection fraction < 50%), valve disease (signiﬁcant regurgitation or
stenosis in transthoracic echocardiography), chronic obstructive
pulmonary disease (FEV1/FVC <70%), renal insufﬁciency (estimat-
ed glomerular ﬁltration rate <60 mL/min/1.73m2), malignant
neoplasm and smoking were assessed.; (2) perioperative circum-
stances (use of prophylactic antibiotics, presence of signs of
infection, anticoagulants use); (3) device characteristics (type of
device - pacemaker, implantable cardioverter-deﬁbrillator, cardiac
resynchronized therapy, number of intracardiac leads); (4) number
of procedures before the infection occurred (generator change,
wound revision, lead repositioning and temporary pacemaker use).
2.3. Data analysis
Normally distributed continuous variables were expressed as
mean  standard deviation (SD).
Statistical signiﬁcance of the comparisons was assessed using
the paired t-test and x2 test. Uni- and multi-variate logistic
regression analyses were used to analyze the cause of device-
related infection between cases and controls. Variance inﬂation
factors (VIF) were used to measure co-linearity in the multivariate
logistic analysis; parameters with VIF10 were considered to be
co-linear. Parameters with co-linearity were excluded from the
multivariate logistic regression analysis. A p-value <0.05 was
considered statistically signiﬁcant. Analyses were performed using
SPSS v19 (SPSS Inc., Chicago, IL, USA) and SAS version 9.2 (SAS
Institute Inc., Cary, NC, USA.)
3. Results
A total of 1307 patients underwent cardiac device implantation
during the study period. Of these, 49.6% were male, and the mean
age was 61.514.2 years. There were 1130 patients (86.5%) who
received pacemaker implantation, 147 (11.2%) who received an ICD
and only 30 patients (2.3%) who received CRT. Over a total of
9091.9 device-years, the incidence of infectious complications was
1.3/1000 device-years (Table 1), based on the 12 patients with an
infection. There was a higher incidence of infectious complications
with ICD (5.1/1000 device-year) than other cardiac devices, and no
infectious complications were observed among the patients with CRT
implantation. Of the 12 patients with infection, 7 patients (0.5%) had a
pocket infection only and 5 patients (0.4%) had infective endocarditis.
The mean duration from the time of implantation to infection (range)
was 2.021.65 years (6 days to 2481 days) (Table 1).
Table 2 compares demographic and clinical characteristics
between patients with and without infections complications.
There were no signiﬁcant differences in gender, echocardiographic
ﬁndings or lab ﬁndings between the two groups. The proportion of
patients with renal insufﬁciency and valvular heart disease was
higher in the control group than the case group, and there was no type
ICD CRT p-value
(86.5) 147 (11.2) 30 (2.3)
13.7 53.614.7 64.113.6 <0.001
(44.0) 123 (83.7) 15 (50.0) <0.001
7 579.99 69.68
(0.8) 3 (2.0)
 5.1
(0.4) 2 (1.4)
(0.4) 1 (0.7)
d therapy, FU: follow-up.
Table 2
Comparison of demographic and clinical characteristics in patients with and
without infectious complications: Case control study (1:2 matched)
Control (n=24) Case (n=12) p-value
Age 68.512.3 56.718.0 0.056
Gender (male; n,%) 13 (45.80) 7 (41.07) 0.819
Device and procedure related factors
No. of leads 1.50.5 1.80.5 0.224
No. of prior procedures 0.040.21 0.751.1 0.056
Hematoma 4.20% 8.30% 0.619
Antiplatelet agent 41.70% 25.00% 0.393
Hospital duration 5.31 2.91.9 0.078
Underlying disease
Hypertension (n,%) 16 (66.70) 5 (41.7) 0.16
Diabetes mellitus (n,%) 7 (29.20) 1 (8.3) 0.109
Myocardial infarction (n,%) 1 (4.2) 2 (16.7) 0.314
Heart failure (n,%) 3 (12.5) 1 (8.3) 0.717
Valve disease (n,%) 13 (54.20) 2 (16.7) 0.032
COPD (n,%) 0 (0) 0 (0) -
Renal disease (n,%) 4 (16.60) 0 (0) 0.043
Cancer (n,%) 0 (0) 0 (0) -
Charlson comorbidity index 2.12.8 0.50.80 0.014
Smoking (n,%) 7 (29.20) 4 (33.3) 0.805
Echocardiographic ﬁndings
Ejection fraction 62.96.2 64.810.3 0.718
E/E’ 14.05.8 11.04.0 0.176
Laboratory ﬁndings
WBC (10^3/uL) 7488.83017.8 6876.71568.2 0.516
Neutrophil (%) 59.314.3 56.914.5 0.634
Hemoglobin (g/dL) 13.21.6 13.91.9 0.262
Platelet (10^3/uL) 234.692.5 233.146.7 0.958
Hemoglobin A1c (%) 6.70.9 6.50.6 0.69
Creatinine (mg/dL) 1.10.4 0.90.2 0.122
eGFR (ml/min/1.73m2) 72.025.5 93.728.6 0.031
CRP (mg/L) 24.8 30.742.1 0.929
NTproBNP (pg/mL) 1033.91546.8 216.4127.6 0.182
CK (IU/L) 137.4124.2 78 0.368
CK-MB (ng/mL) 3.74.1 1.80.3 0.441
TnT (ng/mL) 0.030.077 0.010.01 0.536
AST (IU/L) 32.419.6 21.36.2 0.065
ALT (IU/L) 41.147.2 20.911.7 0.058
COPD: chronic obstructive pulmonary disease, WBC: white blood cell, eGFR:
estimated glomerular ﬁltration rate, CRP: C - reactive protein, NTproBNP: N-
terminal prohormone of brain natriuretic peptide, CK: creatine kinase, TnT:
troponin T, AST: aspartate aminotransferase, ALT: alanine aminotransferase.
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Charlson comorbidity index was higher in the control group, but
was an insigniﬁcant variable in the multivariate analysis
(p=0.0936) (Table 3). The multivariate analysis indicated that
patients with infection had a greater number of prior procedures
including wound revision, generator exchange or scar revision
(OR=10.87, 95% CI 1.108->999, p=0.0402) (Table 3).
Table 4 lists the clinical characteristics of each patient with
cardiac device infection. The pathogens thereof were identiﬁed in
six patients, and included Staphylococcus aureus (S. aureus), two
cases of coagulase-negative staphylococcus, Enterococcus faecium,
and two cases of gram negative bacilli (Enterobacter cloacae,
Escherichia coli). The device was removed in all patients: fourTable 3
Risk factors for device-related infections by univariate and multivariate conditional log
Univariate analysis 
OR 95% CI 
Age 0.948 0.899 0.995 
Gender 0.848 0.162 4.195 
Hospital duration 0.73 0.443 1.01 
Charlson score 0.6 0.265 1.002 
No. of leads 2.475 0.458 17.784 
No. of prior procedures 19.334 1.682 >999 
Ejection fraction 1.01 0.961 1.068 
OR: odds ratio, CI: conﬁdence interval.through open heart surgery and eight through percutaneous
extraction.
4. Discussion
To our knowledge, this is the ﬁrst report of infections associated
with cardiac devices in Korea. The long period of observation
allowed us to review long term prognosis of Asian patients with
cardiac devices. Device-related infection was a rare complication,
and repeated procedures were associated with infectious compli-
cations.
According to prior studies, cardiac device-related infection
occurs in about 0.5-3.5% of cases, with an incidence that varies
from 0.55 to 4.82 per 1000 device-years.5,8–12 CIED-related
infection increased 5.8% from 1996 to 2006 even though CIED
implantation only increased 2.6% during the same time period.15,22
In our study, 0.9% of patients with cardiac devices had infectious
complications, and the overall incidence was 1.3/1000 device-
years. This low incidence matches those reported in previous
studies. Nevertheless. the indications for CIED implantation are
widening23–25 and the number of patients susceptible to infection
(due to old age and various underlying diseases) is increasing.
Thus, the actual number of cases of CIED infection may greatly
expand in the near future. Despite its low incidence, CIED infection
is an important complication, the consequences of which are quite
serious: endocarditis related with device infection increases
mortality,26,27 and most cases require device removal,28,29 which
involves risks of cardiac perforation or open thoracotomy.30
Several earlier studies showed that factors associated with
procedures included early intervention, more than two leads,
device replacement or revision and placement of temporary pacing
wire.1,8,12,14 Patient-related factors included diabetes, renal failure,
heart failure and male sex.1,12,31 Some researchers have pointed
out that corticosteroids or anticoagulation are related to CIED
infection.8,12,28,31,32 There have also been some reports that the
number of cardiac device operations is independently related to a
higher risk of infection.12,33
In our case-control study, repeated procedures were a
signiﬁcant risk factor for infectious complications. This ﬁnding is
consistent with previous studies. We were unable to analyze the
inﬂuence of renal dysfunction or heart failure because of the low
incidence of these diseases in our study population. Herce et al.
evaluated risk factors for infection of implantable cardiac devices
with data from a registry of 2469 patients in a French hospital
between 1996 and 2007.1 Their study showed the presence of
diabetes and underlying heart disease to be risk factors for
infection after cardiac device implantation. Meanwhile, others
have reported contrasting results. In a report by Greenspon et al.,
CIED infection was lower in patients with diabetes (Odds ratio:
0.91; 95% CI: 0.86 to 0.96; p <0.001),34 and others described
diabetes as an insigniﬁcant risk factor.8,32 In our study group, the
prevalence of diabetes in the case group (29.2%) was insigniﬁcantly
higher than that in the control group (8.3%); moreover, theistic regression analysis
Multivariate analysis
p-value OR 95% CI p-value
0.0304 1.02 0.932 1.13 0.72
1
0.0619
0.0517 0.523 0.103 1.067 0.0936
0.4001
0.011 10.872 1.108 >999 0.0402
0.7504
Table 4
Clinical characteristics of each patient with a cardiac device infection
Age Gender Local manifestation Fever TTE Device type Prior procedure Time
interval
Local
culture
Lead culture Blood culture Outcome
1 80 F Inﬂammation(redness,
discharge)
+ - PM 0 6 Negative Negative Negative Percutaneous
extraction
Recurrent skin
eruption over the
implantation site
2 73 F Inﬂammation(hematoma,
serosanguineous
discharge)
- - PM 0 10 Negative Negative Negative Percutaneous
extraction
3 60 M Inﬂammation(skin
discoloration, tenderness)
- - PM 1(wound
revision)
34 Enterobacter
cloacae
Enterobacter
cloacae
Negative Percutaneous
extraction
Overlying skin thinning
and necrosis
4 38 F Inﬂammation(redness,
local heating, tenderness)
+ Negative ICD 2(pacemaker
revision, scar
revision)
65 MRSA MRSA MRSA Surgical
removal
Pacemaker insertion
under the left pectoralis
major muscle via the
axillary incision
(cosmetic cause)
5 34 M Inﬂammation(yellowish
pus)
- - PM 1(generator
repositioning)
191 Negative Negative Negative Percutaneous
extraction
6 73 F Inﬂammation(yellowish
discharge, skin defect)
- - ICD 0 468 Negative - Negative Surgical
removal
7 43 M erosion, tenderness - - PM 0 566 Negative Negative Negative Percutaneous
extraction
8 57 M Inﬂammation(swelling,
tenderness)
- - PM 1(re-implantation
with device
protrusion)
611 MRCNS MRCNS Negative Percutaneous
extraction
9 39 F Inﬂammation(pus
discharge)
- - PM 1(generator
repositioning)
876 E. faecium Negative Negative Percutaneous
extraction
10 69 M Inﬂammation(skin erosion,
discharge)
- - PM 2(wound
debridement
and revision)
938 MSCNS MSCNS Negative Surgical
removal
11 79 F Inﬂammation(skin erosion,
wire exposure)
+ Vegetation PM 0 1013 Negative Negative Negative Surgical
removal
Skin erosion by nail
scratch, secondary
septic pneumonia
12 35 M Inﬂammation(wound
dehiscence, pus-like
discharge)
- Negative ICD 1(lead exchange) 2481 ESBL(-) E. coli - Negative Percutaneous
extraction
TTE: Transthoracic echocardiography, MRSA: Methicillin–-resistant staphylococcus aureus, MRCNS: Methicillin-resistant coagulase negative staphylococci, MSCNS: Methicillin-sensitive coagulase negative staphylococci, ESBL:
Extended spectrum beta-lactamase.
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factor for infectious complications in our case control study, even
after including diabetes in the multivariate model. Diabetes
mellitus is usually related with wound infection, but has no
negative inﬂuences under tight glycemic control.35,36 In the
present study, diabetes in all enrolled patients was controlled
well, with a mean HbA1c of 6.550.52%. Thus, we suggest that the
burden of repeatedly undergoing medical procedures inﬂuences the
occurrence of CIED infection much more than patient characteristics,
including underlying disease.
In our study, the pathogens of infectious complications were
identiﬁed in only 6 patients. Previous studies showed that bacterial
infection is the leading cause of CIED complication, mostly from
skin normal ﬂora,37 among which S. aureus and coagulase negative
staphylococcus comprise the majority of infections.38,39 In our
study participants, one case of S. aureus and two cases of coagulase
negative staphylococcus were observed. The S. aureus and one of
the coagulase negative staphylococcus cultures were methicillin
resistance. Reportedly, the risk of methicillin-resistance is higher
within a year of implantation;40 however, in our study, we could
not ﬁnd a distinct relationship in patients with methicillin-
resistant bacteria, due to the small sample size.
We also observed a relatively higher infection rate in patients
with ICD implantation (statistically insigniﬁcant). The ICD
generator is bigger and heavier than pacemakers, and thus
requires a longer incision and bigger pocket. Patients with ICD
exhibit more tension on covering skin and a chance of bigger dead
space. As well, most patients that require ICD are survivors of
cardiac arrest. Cardiac arrest and resuscitation cause cardiac
stunning and transient multiple organ injury. Although their
cardiac dysfunction reversed fully from stress, these systemic
effects could have had a negative inﬂuence on their general
condition and a chance of infection.
All of the patients with device infection had their devices
removed. Eight patients underwent percutaneous removal, and the
other 4 patients underwent open thoracotomy. There was no CIED
infection-related death in our study participants. The reported
inpatient mortality related with CIED infection ranges from 4.69%
to 17% in cases of endocarditis.34,41,42
5. Limitations
This study has several limitations. First, this is a retrospective
study. We could not analyze the effect of renal insufﬁciency or
heart failure because there were only few patients with
comorbidities. We only included patients from a single referral
center, and so our ﬁndings may not be broadly applicable. Despite
these limitations, this is the ﬁrst report about the incidence and
risk factors of CIED infection in South Korea. And it is meaningful
that we saw long term after-effects associated with cardiac device
implantation over 23 years of observation (1990-2013).
Our ﬁndings could be helpful in the both clinical setting and
further research on CIED infections.
6. Conclusions
Even though the incidence of CIED-related infections was low in
South Korea, physicians should closely monitor for complications
in patients who receive repeated procedures.
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